Additionally, TLR7 inhibition has been shown to reduce the accumulation of αSyn in animal models of PD, suggesting that TLR7 may be a potential therapeutic target for the treatment of synucleinopathies [91]. The gene discussed is TLR7; the disease is synucleinopathy.